Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: A case series and a literature review of therapeutic approaches

Dermatology

Volumn 220, Issue 3, 2010, Pages 243-248

  Nikolaou, V A ^a   Stratigos, A ^a   Antoniou, C ^a   Kiagia, M ^b   Nikolaou, C ^a   Katsambas, A ^a   Syrigos, K ^b  

^a ANDREAS SYGROS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acneiform uption; Cetuximab; Epidermal growth factor receptorinhibitors; Erlotinib; Pimecrolimus

Indexed keywords

CETUXIMAB; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; METRONIDAZOLE; MINOCYCLINE; PANITUMUMAB; PIMECROLIMUS;

ADULT; AGED; ARTICLE; BURNING SENSATION; CASE STUDY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; INFORMATION RETRIEVAL; LUNG NON SMALL CELL CANCER; MALE; PAPULAR SKIN DISEASE; PRIORITY JOURNAL; PUSTULE; SKIN DEFECT; SQUAMOUS CELL CARCINOMA;

AGED; ANTINEOPLASTIC AGENTS; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; MINOCYCLINE; NEOPLASMS; OINTMENTS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROSACEA; TACROLIMUS; TREATMENT OUTCOME;

EID: 77951879709     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277430     Document Type: Article

References (28)

1. Shepherd FA, Rodriques Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-132.
2. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
4. Duvic M: EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol 2009; 9: 285-294.
5. Rigopoulos D, Gregoriou S, Belyayeva Y, Larios G, Gkouvi A, Katsambas A: Acute paronychia caused by lapatinib therapy. Clin Exp Dermatol 2009; 34: 94-95.
6. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL: Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113: 847-853.
7. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC: Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390-5396.
8. Shah N, Kris M, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA: Practical management of patients with non-small cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23: 165-174.
9. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
10. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel antiinflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-273.
11. Gupta AK, Chow M: Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493-503.
12. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J: Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005; 153: 849-851.
13. Lacouture ME, Basti S, Patel J, Benson AI: The Series clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006; 4: 236-238.
14. Matheis P, Socinski MA, Burkhart C, Warren S, Thomas NE: Treatment of gefitinibassociated folliculitis. J Am Acad Dermatol 2006; 55: 710-713.
15. Alexandrescu D, Vaillant J, Dasanu C: Effect of treatment with a colloidal oatmeal lotion on the acneiform eruption induced by epidermal growth factor receptor and multiple tyrosine kinase inhibitors. Clin Exp Dermatol 2007; 32: 71-74.
16. De Witt CA, Siroy AE, Stone SP: Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007; 56: 500-505.
17. Pomerantz RG, Chirinos RE, Falo LD, Geskin LJ: Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol 2008; 144: 949-950.
18. Segaert S, Van Cutsem E: Clinical management of EGFRI dermatologic toxicities: the European perspective. Oncology (Williston Park) 2007; 21: 22-26.
19. Lacouture ME, Melosky BL: Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Ther Lett 2007; 12: 1-5.
20. Kimyai-Asadi A, Jih MH: Follicular toxic effects of chimeric antiepidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138: 129-131.
21. Lee HM, Ciancio SG, Tüter G, Ryan ME, Komaroff E, Golub LM: Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004; 75: 453-463.
22. Nieman GF, Zerler BR: A role for the antiinflammatory properties of tetracyclines in the prevention of acute lung injury. Curr Med Chem 2001; 8: 317-325.
23. Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME: Epidermaol growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-621.
24. Luger T, Paul C: Potential new indications of topical calcineurin inhibitors. Dermatology 2007; 215(suppl 1):45-54.
25. Jacobi A, Braeutigam M, Mahler V, Schultz E, Hertl M: Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week openlabel study. Dermatology 2008; 216: 133-136.
26. Margolis DJ, Hoffstad O, Bilker W: Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-295.
27. Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, Seeger JD: Topical treatments with pimecrolimus and medium-to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009; 219: 7-21.
28. Mascia F, Mariani V, Girolomoni G, Pastore S: Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303-312.